APL-101

DRUG4 trials

Sponsors

Apollomics Inc., Apollomics (Australia) Pty. Ltd., Washington University School of Medicine

Conditions

BioequivalenceHepatocellular CarcinomaMetastatic Non Small Cell Lung CancerRenal Cell CarcinomaSelect advanced solid tumors and Non-Small Cell Lung Cancer with MET aberrations

Phase 1

APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC

TerminatedNCT03655613

Apollomics (Australia) Pty. Ltd.Hepatocellular Carcinoma, Renal Cell Carcinoma

Start: 2018-09-05End: 2021-12-15Updated: 2022-05-06

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Active, not recruitingNCT04743505

Washington University School of MedicineMetastatic Non Small Cell Lung Cancer

Start: 2022-01-18End: 2029-12-31Updated: 2026-01-20

A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants

Apollomics Inc.Bioequivalence

Start: 2022-05-20End: 2022-12-31Target: 48Updated: 2022-06-15

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met Exon14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

RecruitingCTIS2024-514542-37-00

Apollomics Inc.Select advanced solid tumors and Non-Small Cell Lung Cancer with MET aberrations

Start: 2020-08-13Target: 271Updated: 2024-10-01